A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis

Stopped Due to development challenges associated with the SARS-CoV-2 pandemic and emerging nonclinical data

Conditions

• Healthy Volunteers
• Idiopathic Pulmonary Fibrosis

Interventions

• DRUG: IDL-2965 Oral Capsule
• DRUG: Placebos

Sponsor

Indalo Therapeutics, Inc.